Product category:
Nucleic acid sequencing and synthesis
News Release from: Applied Biosystems | Subject: TaqMan drug metabolism genotyping assays
Edited by the Laboratorytalk Editorial
Team on 19 May 2006
Validating biomarkers for cancer
research
Applied Biosystems enters collaboration with the Core Genotyping Facility, SAIC-Frederick, a contractor for the National Cancer Institute (NCI), on a series of biomarker studies for cancer research
The NCI-funded Core Genotyping Facility will use Applied Biosystems's entire TaqMan drug metabolism genotyping assay collection to examine genetic variations in the HapMap and SNP500Cancer samples in order to validate additional cancer biomarkers In support of the NCI, the Core Genotyping Facility is using more than 2400 TaqMan drug metabolism genotyping assays to generate the genotypes for samples from the International HapMap project and from NCI's SNP500Cancer standard sample panel
This article was originally published on Laboratorytalk on 23 Aug 2005 at 8.00am (UK)
Related stories
Preliminary version of TaqMan assays available
A preliminary version of Applied Biosystems' TaqMan drug metabolism genotyping assays is now available through an early-access customer programme.
Value of TaqMan drug assays is validated
Scientists from Applied Biosystems presented data demonstrating superior accuracy of TaqMan drug metabolism genotyping assays in identifying variation in genes that code for drug metabolism enzymes
In addition, select assays with significant correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma.
"The objective of this study is to better understand the genetic differences associated with individual responses to cancer treatment," said Dennis Gilbert, chief scientific officer for Applied Biosystems.
"Because our TaqMan drug metabolism genotyping assays were developed using extensive computational analysis in combination with assay optimization and validation that identified novel and well-known gene variants, we believe they represent the most complete set of drug metabolism assays available to the scientific research community".
Further reading
High throughput nucleic acid purification
Applied Biosystems has released the ABI Prism 6100 nucleic acid PrepStation for high throughput purification of RNA and DNA, taking only 30 minutes to isolate total RNA from cells
Cattle DNA typing kit
Applied BioSystems says that complete traceability from farm to supermarket is now a reality, providing a new tool to establish the safety of food products
Rapid integration solutions
Applied Biosystems offers Rapid Integration Solutions - specialised informatics packages that integrate and automate instruments, robots, software and databases
"We are pleased the SAIC-Frederick, under contract to the NCI, has selected them for this important project and are confident the assays will identify genetic variations important to various cancers for future pharmacogenetic studies and treatment guidelines".
The Core Genotyping Facility will use samples from the HapMap project, SNP500Cancer, and Human Diversity Panel as controls to evaluate the genes included in the TaqMan drug metabolism genotyping assays.
Applied Biosystems and the Core Genotyping Facility will jointly analyse the resulting genotype data, and compare resulting data with previously published genotype and/or sequencing data for the same variants and individuals.
Final data meeting concordance/Mendelian transmission thresholds will be posted on the SNP500Cancer website, displaying the observed minor allele frequency, context sequences, and assay ordering information.
The collaborators also plan to publish further findings.
The TaqMan drug metabolism genotyping assays are a collection of ready-to-use assays that detect polymorphisms within approximately 220 genes identified as phase I, phase II, and transport genes within the drug metabolism pathways.
It is believed that some polymorphisms within these genes cause differences for drug efficacy between individuals.
Other polymorphisms within these genes are believed to be associated with individuals who have a higher risk for certain diseases.
The TaqMan drug metabolism genotyping assay collection comprises more than 2400 individual assays for research purposes only.
One tube contains two allele specific TaqMan probes and a primer pair to detect individual polymorphisms.
All assays have been extensively characterised within this collection with 180 genotypes generated per assay.
Where possible, information from the common public allele websites has been mapped to individual assays.
• Applied Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
